Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240822 | 0.94 | GPR119 (0.85) | GPR119 | |
| SCHEMBL3236483 | 0.94 | GPR119 (0.85) | GPR119 | |
| SCHEMBL3245167 | 0.89 | GPR119 (0.70) | GPR119 | |
| SCHEMBL3238729 | 0.88 | GPR119 (0.81) | GPR119 | |
| SCHEMBL17091636 | 0.88 | GPR119 (0.67) | GPR119 | |
| SCHEMBL3240476 | 0.88 | GPR119 (0.82) | GPR119 | |
| SCHEMBL3241643 | 0.88 | GPR119 (0.68) | GPR119 | |
| SCHEMBL3245045 | 0.87 | GPR119 (0.67) | GPR119 | |
| SCHEMBL3240823 | 0.87 | GPR119 (0.67) | GPR119 | |
| SCHEMBL3239748 | 0.87 | GPR119 (0.67) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210886-B1 | PYRIMIDYL INDOLINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-09-23 | — | — | EP | claimed |
| US-8232287-B2 | Pyrimidyl indoline compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-31 | — | — | US | claimed |
| US-20100292259-A1 | PYRIMIDYL INDOLINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-11-18 | — | — | US | claimed |
| EP-2210886-A1 | PYRIMIDYL INDOLINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-07-28 | — | — | EP | claimed |
| EP-2210886-B1 | PYRIMIDYL INDOLINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-09-23 | — | — | EP | disclosed |
| US-8232287-B2 | Pyrimidyl indoline compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20100292259-A1 | PYRIMIDYL INDOLINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-2210886-A1 | PYRIMIDYL INDOLINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292259-A1 | PYRIMIDYL INDOLINE COMPOUND | GPR119, SLC5A2, SLC5A1 | GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.